221 related articles for article (PubMed ID: 24740981)
1. Current evidence of anti-tumor necrosis factor α treatment efficacy in childhood chronic uveitis: a systematic review and meta-analysis approach of individual drugs.
Simonini G; Druce K; Cimaz R; Macfarlane GJ; Jones GT
Arthritis Care Res (Hoboken); 2014 Jul; 66(7):1073-84. PubMed ID: 24740981
[TBL] [Abstract][Full Text] [Related]
2. Changing evidence over time: updated meta-analysis regarding anti-TNF efficacy in childhood chronic uveitis.
Maccora I; Fusco E; Marrani E; Ramanan AV; Simonini G
Rheumatology (Oxford); 2021 Feb; 60(2):568-587. PubMed ID: 33219694
[TBL] [Abstract][Full Text] [Related]
3. Does switching anti-TNFα biologic agents represent an effective option in childhood chronic uveitis: the evidence from a systematic review and meta-analysis approach.
Simonini G; Katie D; Cimaz R; Macfarlane GJ; Jones GT
Semin Arthritis Rheum; 2014 Aug; 44(1):39-46. PubMed ID: 24709278
[TBL] [Abstract][Full Text] [Related]
4. Non-anti-TNF biologic modifier drugs in non-infectious refractory chronic uveitis: The current evidence from a systematic review.
Simonini G; Cimaz R; Jones GT; Macfarlane GJ
Semin Arthritis Rheum; 2015 Oct; 45(2):238-50. PubMed ID: 26164255
[TBL] [Abstract][Full Text] [Related]
5. Current evidence of methotrexate efficacy in childhood chronic uveitis: a systematic review and meta-analysis approach.
Simonini G; Paudyal P; Jones GT; Cimaz R; Macfarlane GJ
Rheumatology (Oxford); 2013 May; 52(5):825-31. PubMed ID: 22879466
[TBL] [Abstract][Full Text] [Related]
6. Remission in ankylosing spondylitis treated with anti-TNF-α drugs: a national multicentre study.
Spadaro A; Lubrano E; Marchesoni A; D'Angelo S; Ramonda R; Addimanda O; Perrotta FM; Olivieri I; Punzi L; Salvarani C
Rheumatology (Oxford); 2013 Oct; 52(10):1914-9. PubMed ID: 23878312
[TBL] [Abstract][Full Text] [Related]
7. Tumor necrosis factor antagonists: different kinetics and/or mechanisms of action may explain differences in the risk for developing granulomatous infection.
Furst DE; Wallis R; Broder M; Beenhouwer DO
Semin Arthritis Rheum; 2006 Dec; 36(3):159-67. PubMed ID: 16884970
[TBL] [Abstract][Full Text] [Related]
8. Switching from infliximab or etanercept to adalimumab in resistant or intolerant patients with spondyloarthritis: a 4-year study.
Spadaro A; Punzi L; Marchesoni A; Lubrano E; Mathieu A; Cantini F; Olivieri I; Salvarani C; Scarpa R; Scrivo R; Ramonda R; Porru G; D'Angelo S; Catanoso M; Atteno M; Valesini G
Rheumatology (Oxford); 2010 Jun; 49(6):1107-11. PubMed ID: 20223813
[TBL] [Abstract][Full Text] [Related]
9. Uveitis Reactivation in Children Treated With Tumor Necrosis Factor Alpha Inhibitors.
Lerman MA; Lewen MD; Kempen JH; Mills MD
Am J Ophthalmol; 2015 Jul; 160(1):193-200.e1. PubMed ID: 25892124
[TBL] [Abstract][Full Text] [Related]
10. Anti-Tumor Necrosis Factor Treatment in the Management of Pediatric Noninfectious Uveitis: Infliximab Versus Adalimumab.
Ucan Gunduz G; Yalcinbayir O; Cekic S; Yildiz M; Kilic SS
J Ocul Pharmacol Ther; 2021 May; 37(4):236-240. PubMed ID: 33512278
[No Abstract] [Full Text] [Related]
11. Predictive factors for partial remission according to the Ankylosing Spondylitis Assessment Study working group in patients with ankylosing spondylitis treated with anti-TNFα drugs.
Perrotta FM; Addimanda O; Ramonda R; D'Angelo S; Lubrano E; Marchesoni A; Olivieri I; Punzi L; Salvarani C; Spadaro A
Reumatismo; 2014 Nov; 66(3):208-14. PubMed ID: 25376955
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of etanercept and adalimumab in children aged 2 to 4 years with juvenile idiopathic arthritis.
Windschall D; Horneff G
Clin Rheumatol; 2016 Dec; 35(12):2925-2931. PubMed ID: 27709443
[TBL] [Abstract][Full Text] [Related]
13. The effect of anti-tumor necrosis factor alpha agents on the outcome in pediatric uveitis of diverse etiologies.
Deitch I; Amer R; Tomkins-Netzer O; Habot-Wilner Z; Friling R; Neumann R; Kramer M
Graefes Arch Clin Exp Ophthalmol; 2018 Apr; 256(4):801-808. PubMed ID: 29455252
[TBL] [Abstract][Full Text] [Related]
14. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
Hyrich KL; Watson KD; Silman AJ; Symmons DP;
Rheumatology (Oxford); 2006 Dec; 45(12):1558-65. PubMed ID: 16705046
[TBL] [Abstract][Full Text] [Related]
15. Long-term retention rates of adalimumab and infliximab in non-infectious intermediate, posterior, and panuveitis.
Fabiani C; Vitale A; Emmi G; Bitossi A; Lopalco G; Sota J; Guerriero S; Orlando I; Capozzoli M; Fusco F; Rana F; Iannone F; Frediani B; Galeazzi M; Vannozzi L; Tosi GM; Cantarini L
Clin Rheumatol; 2019 Jan; 38(1):63-70. PubMed ID: 29611087
[TBL] [Abstract][Full Text] [Related]
16. Long-term safety of etanercept and adalimumab compared to methotrexate in patients with juvenile idiopathic arthritis (JIA).
Klotsche J; Niewerth M; Haas JP; Huppertz HI; Zink A; Horneff G; Minden K
Ann Rheum Dis; 2016 May; 75(5):855-61. PubMed ID: 25926155
[TBL] [Abstract][Full Text] [Related]
17. The clinical effectiveness and cost-effectiveness of abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis: a systematic review and economic evaluation.
Shepherd J; Cooper K; Harris P; Picot J; Rose M
Health Technol Assess; 2016 Apr; 20(34):1-222. PubMed ID: 27135404
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of adalimumab in the treatment of non-infectious uveitis: a meta-analysis and systematic review.
Ming S; Xie K; He H; Li Y; Lei B
Drug Des Devel Ther; 2018; 12():2005-2016. PubMed ID: 30013320
[TBL] [Abstract][Full Text] [Related]
19. Infliximab Versus Adalimumab in the Treatment of Refractory Inflammatory Uveitis: A Multicenter Study From the French Uveitis Network.
Vallet H; Seve P; Biard L; Baptiste Fraison J; Bielefeld P; Perard L; Bienvenu B; Abad S; Rigolet A; Deroux A; Sene D; Perlat A; Marie I; Feurer E; Hachulla E; Fain O; Clavel G; Riviere S; Bouche PA; Gueudry J; Pugnet G; Le Hoang P; Resche Rigon M; Cacoub P; Bodaghi B; Saadoun D;
Arthritis Rheumatol; 2016 Jun; 68(6):1522-30. PubMed ID: 27015607
[TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of infliximab and adalimumab for refractory uveitis in juvenile idiopathic arthritis: 1-year followup data from the Italian Registry.
Zannin ME; Birolo C; Gerloni VM; Miserocchi E; Pontikaki I; Paroli MP; Bracaglia C; Shardlow A; Parentin F; Cimaz R; Simonini G; Falcini F; Corona F; Viola S; De Marco R; Breda L; La Torre F; Vittadello F; Martini G; Zulian F
J Rheumatol; 2013 Jan; 40(1):74-9. PubMed ID: 23118110
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
